Twenty-one patients (16.9%) harbored co-occurring lung cancer driver alterations, including one ERBB2 amplification (amp), one ERBB2 mutation, four RET mutations, five MET amp, one ROS1 amp, two MET mutations, two ALK mutations, one BRAF V600E, one BRAF mutation and one KRAS G13C, one KRAS G13D and one KRAS G12V. This evidence concerns the gene KRAS and lung carcinoma.